CYTK4:00 PMCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)cytokinetics.com
CYTK7:30 AMCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)cytokinetics.com
CYTK4:00 PMCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conferencecytokinetics.com
CYTK10:06 AMCytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026cytokinetics.com
CYTK10:51 AMCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Millioncytokinetics.com
CYTK11:00 PMCytokinetics Announces Pricing of Upsized Public Offering of Common Stockcytokinetics.com
CYTK4:05 PMCytokinetics Reports First Quarter 2026 Financial Results and Provides Business Updatecytokinetics.com
CYTK7:30 AMCytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic CardiomyopathyTrial Results • Phase 3cytokinetics.com
CYTK4:00 PMCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026cytokinetics.com
CYTK7:30 AMCytokinetics Announces Ten Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congresscytokinetics.com
CYTK4:00 PMCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)cytokinetics.com
CYTK4:00 PMCytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conferencecytokinetics.com
CYTK4:00 PMCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)cytokinetics.com
CYTK8:00 AMCytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expocytokinetics.com